Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Bronchiolitis Market

DelveInsight’s ‘Bronchiolitis – Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Bronchiolitis, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, France, Italy, Spain and the United Kingdom), and Japan.

 

The Bronchiolitis market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Bronchiolitis symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Bronchiolitis symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

Geographies Covered

  • The United States
  • EU5
  • Japan

Study Period: 2018–2030

Bronchiolitis Disease Understanding and Treatment Algorithm

Bronchiolitis Overview

Bronchiolitis is most often described as a virus‐induced inflammation of small bronchioles and their surrounding tissue. Caused by respiratory viruses that invade the epithelial cells of the small airways, it begins with upper respiratory tract symptoms of rhinorrhoea followed by persistent cough, tachypnoea, chest wall recessions and widespread crackles, wheeze or both.

 

At pathologic examination, bronchiolitis is typically divided into two broad categories: cellular bronchiolitis and constrictive (fibrotic) bronchiolitis. Viruses are now known to be the prime cause of the syndrome and the associated characteristic pathology of the lower respiratory tract. The most common infectious agent causing acute bronchiolitis in children is the respiratory syncytial virus.

 

Bronchiolitis shows a yearly seasonal pattern that varies according to geography and climate. Globally, independent of region, respiratory syncytial virus infection peaks consistently during annual or biannual epidemics. Although the peak and duration of these epidemics vary worldwide, they are consistent year-to-year within a country.

 

Prognosis is great, with most children recovering in 3–5 days without sequelae, although wheezing and cough may continue for 2–4 weeks. Bronchiolitis is more common in boys, especially among children with more severe illness. Other factors that have been associated with a greater likelihood of severe illness include young maternal age, lower cord blood antibody titers to RSV, lower socioeconomic status, tobacco smoke exposure.

 

Bronchiolitis is mainly a clinical diagnosis. The diagnosis and severity of the illness should be made after eliciting a good history of present illness and based on the individual’s clinical manifestations. Treatment of bronchiolitis is supportive, and most individuals can be managed at home with hydration and comfort measures. Some cases with RSV lower respiratory infection present with critical hypoxemia, apnea, or respiratory failure and may immediately require intensive care.

 

In recent years, immunoprophylaxis with palivizumab, a humanized monoclonal antibody capable of neutralizing RSV, has effectively reduced hospitalization rates relating to RSV infections. The current research and development focus for most companies is in developing a broad spectrum RSV vaccine.

 

Bronchiolitis Diagnosis and Treatment

It covers conventional and current medical therapies and diagnosis available in the Bronchiolitis market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the 7MM.

 

The DelveInsight Bronchiolitis market report thoroughly understands Bronchiolitis symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Bronchiolitis symptoms of treatment algorithms and treatment guidelines for Bronchiolitis symptoms in the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan.

Bronchiolitis Epidemiology

The epidemiology division’s Bronchiolitis symptoms provide insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions.

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Bronchiolitis epidemiology, segmented as incident cases of Bronchiolitis and incidence of Bronchiolitis by etiologies.The report includes the incident Bronchiolitis symptoms in the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

 

The total 7MM incident cases of Bronchiolitis in 2020 was 8,026,904. Incident population of Bronchiolitis in 7MM is expected to increase at a CAGR of 0.01% for the study period 2018–2030.

Bronchiolitis Drug Chapters

The drug chapter segment of the report encloses detailed analysis of Bronchiolitis marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Bronchiolitis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

Management of bronchiolitis is  mostly supportive, assisting hydration and hypoxemia until improvement. With increased respiratory rate and nasal secretions, oral feeding is challenged, and those with severe disease require assistance with feeding by enteral or parenteral means. The threshold for supporting hydration is typically when an infant’s intake is reduced to 50–75% of the usual volume. Support for dehydration can be provided in the form of encouraging frequent small aliquots of oral, nasogastric, or intravenous hydration without a single modality being superior to the others. Severe bronchiolitis may be associated with greater potential for hyponatremia, and management with hypotonic fluids may also be associated with less favorable outcomes.

 

Ribavirin, a synthetic guanosine analog, is the only antiviral medication studied for the treatment of bronchiolitis. Its use is not routinely recommended by current guidelines.

 

The absence of an effective treatment for bronchiolitis makes prevention the best choice to reduce the burden of the disease and its impact on social health. In recent years, immunoprophylaxis with palivizumab, a humanized monoclonal antibody capable of neutralizing RSV, has effectively reduced hospitalization rates relating to RSV infections.

Products detail in the report…

 

Bronchiolitis Emerging Drugs

 

Inmunotek is developing MV130 (Bactek) for the treatment of Bronchiolitis. MV130, which contains heat-inactivated bacteria besides inducing specific T cell immunity against the bacteria included in preparation also shows an enhanced T cell response to unrelated flu antigen. It triggers TLR and NLR signalling pathways on DCs releasing trained immunity hallmarks.

 

Many new therapies for Bronchiolitis are in various phases of  development  which have novel targets and mechanisms of action.

Bronchiolitis Market Outlook

The Bronchiolitis market outlook of the report helps build the detailed comprehension of the historic, current and forecasted Bronchiolitis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.

 

This segment gives a thorough detail of Bronchiolitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight clearly.

 

According to DelveInsight, the Bronchiolitis market in the 7MM is expected to change during the study period 2018–2030.

 

Key Findings

This section includes a glimpse of the Bronchiolitis market in the United States. The total market size of Bronchiolitis was found to be USD 56.1 Million in 2020, which is further expected to increase by 2030.

 

The United States Market Outlook

This section provides a total of Bronchiolitis market size and market size by therapies in the United States. The pipeline scenario is showing early promise with several therapeutic candidates at different stages of clinical development.

 

EU-5 Countries: Market Outlook

The total Bronchiolitis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided.

 

Japan: Market Outlook

The total Bronchiolitis market size and market size by therapies in Japan are also mentioned.

Bronchiolitis Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers Bronchiolitis market uptake by drugs, patient uptake by therapies, and drug sales.

 

This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows comparing the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Bronchiolitis Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Bronchiolitis key players involved in developing targeted therapeutics.

 

Major players include MV130 (Inmunotek), Nirsevimab (AstraZeneca and Sanofi), RSV F nanoparticle vaccine (Novavax) and MK-1654 (Merck) etc. which are being assessed as potential therapies available in the market in the future.

Products detail in the report…

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, merger, licensing, and patent details for Bronchiolitis emerging therapies.

Reimbursement Scenario in Bronchiolitis

While many individuals wait until their claim has been denied before seeking the services of a Social Security attorney, the patient should consider retaining legal representation before submitting the initial application. By working with an attorney or advocate, the patient will ensure that patient’s claim has sufficient supportive medical evidence and that it will be processed through the Compassionate Allowances program. An attorney will do his or her best to ensure that the patient receives Social Security Disability benefits as quickly as possible and help the patient avoid the lengthy disability appeal process.

KOL  Views

To keep up with current market trends, we take KOLs and SME’s opinion working in Bronchiolitis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or the Bronchiolitis market trend. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Bronchiolitis Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Bronchiolitis, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Bronchiolitis epidemiology and treatment in the  United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • Additionally, an all-inclusive account of both the current and emerging therapies for Bronchiolitis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Bronchiolitis market; historical and forecasted is included in the report, covering drug outreach in the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Bronchiolitis market

Report Highlights

  • In the coming years, the Bronchiolitis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world, which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Bronchiolitis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Bronchiolitis. The launch of emerging therapies will significantly impact the Bronchiolitis market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Bronchiolitis.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Bronchiolitis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Bronchiolitis Pipeline Analysis
  • Bronchiolitis Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Bronchiolitis Report Key Strengths

  • 10-year Forecast
  • The United States Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Market Size by Country
  • Market Size by Therapy

Bronchiolitis Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Emerging Drug Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Bronchiolitis Market share (%) distribution in 2018, and how it would look like in 2030?
  • What would be the Bronchiolitis total market Size as well as market Size by therapies across the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan during the forecast period (2018–2030)?
  • What are the market’s key findings across the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan and historical as well as forecasted epidemiology during the forecast period (2018–2030)?
  • At what CAGR, the Bronchiolitis market is expected to grow by the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan during the forecast period (2018–2030)?
  • What would be the Bronchiolitis market outlook across the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan during the forecast period (2018–2030)?
  • What would be the Bronchiolitis market growth till 2030, and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Bronchiolitis?
  • What is the historical Bronchiolitis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Bronchiolitis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Bronchiolitis?
  • At what CAGR the population is expected to grow during the forecast period (2018–2030)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Bronchiolitis?
  • What are the current treatment guidelines for treating Bronchiolitis in the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan?
  • What are Bronchiolitis marketed drugs and their MOA, regulatory milestones, product development activities, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Bronchiolitis?
  • How many therapies are developed by each company for the treatment of Bronchiolitis?
  • How many emerging therapies are in the mid-stage and late stages of development to treat Bronchiolitis?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Bronchiolitis therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Bronchiolitis and its status?
  • What are the key designations that have been granted for the emerging therapies for Bronchiolitis?
  • What are the global historical and forecasted market of Bronchiolitis?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Bronchiolitis market
  • To understand the future market competition in the Bronchiolitis market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Bronchiolitis in the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Bronchiolitis market
  • To understand the future market competition in the Bronchiolitis market

1. Key Insights

2. Report Introduction

3. Bronchiolitis Market Overview at a Glance

3.1. Market Share (%) Distribution of Bronchiolitis in 2018

3.2. Market Share (%) Distribution of Bronchiolitis in 2030

4. Executive Summary of Bronchiolitis

5. Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Classification

5.4. Causes

5.5. Pathophysiology

5.6. Pathophysiology of RSV Bronchiolitis

5.7. Clinical Manifestation

5.8. Diagnosis

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Incident Patient Population of Bronchiolitis

6.3. Assumption and Rationale

6.4. The United States

6.4.1. Incidence of Bronchiolitis

6.4.2. Incidence of Bronchiolitis by Etiologies

6.5. Germany

6.5.1. Incidence of Bronchiolitis

6.5.2. Incidence of Bronchiolitis by Etiologies

6.6. France

6.6.1. Incidence of Bronchiolitis

6.6.2. Incidence of Bronchiolitis by Etiologies

6.7. Italy

6.7.1. Incidence of Bronchiolitis

6.7.2. Incidence of Bronchiolitis by Etiologies

6.8. Spain

6.8.1. Incidence of Bronchiolitis

6.8.2. Incidence of Bronchiolitis by Etiologies

6.9. United Kingdom

6.9.1. Incidence of Bronchiolitis

6.9.2. Incidence of Bronchiolitis by Etiologies

6.10. Japan

6.10.1. Incidence of Bronchiolitis

6.10.2. Incidence of Bronchiolitis by Etiologies

7. Treatment and Management

8. Diagnostic and Treatment Guidelines

8.1. American Academy of Pediatrics (AAP) Guidelines 2014

8.2. National Institute for Health and Care Excellence (NICE) 2015 Guidelines

8.3. National Health Service (NHS) 2018 Guidelines

9. Patient Journey

10. Case Report

11. Organizations contributing towards Bronchiolitis

12. Emerging Therapies

12.1. MV130: Inmunotek

12.1.1. Drug Description

12.1.2. Clinical Development

12.1.3. Clinical Trials Information

12.1.4. Safety and Efficacy

12.1.5. Product Profile

12.2. Nirsevimab: Sanofi/ AstraZeneca

12.2.1. Drug Description

12.2.2. Product Development Activity

12.2.3. Clinical Development

12.2.4. Clinical Trials Information

12.2.5. Safety and Efficacy

12.2.6. Product Profile

12.3. RSV F Vaccine: Novavax

12.3.1. Drug Description

12.3.2. Clinical Development

12.3.3. Clinical Trials Information

12.3.4. Product Profile

12.4. MK-1654: Merck

12.4.1. Drug Description

12.4.2. Clinical Development

12.4.3. Clinical Trials Information

12.4.4. Safety and Efficacy

12.4.5. Product Profile

13. Dormant Therapies

13.1. MK-0476: Merck

13.1.1. Drug Description

13.1.2. Clinical Development

13.1.3. Clinical Trials Information

13.1.4. Product Profile

14. Discontinued Therapies

14.1. Suptavumab: Regeneron

14.1.1. Drug Description

14.1.2. Product Development Activity

14.1.3. Clinical Development

14.1.4. Clinical Trials Information

14.1.5. Product Profile

15. Bronchiolitis: 7 Major Market Analysis

15.1. Key Findings

15.2. Market Size of Bronchiolitis in 7MM countries

15.3. Bronchiolitis Market Size by Therapies in the 7MM countries

16. Country-wise Market Analysis

16.1. Market Outlook

16.2. United States Market Size

16.2.1. Total Market Size of Bronchiolitis

16.2.2. Market Size of Bronchiolitis by Therapies

16.3. EU-5 Countries

16.3.1. Germany

16.3.1.1. Total Market Size of Bronchiolitis

16.3.1.2. Market Size of Bronchiolitis by Therapies

16.3.2. France

16.3.2.1. Total Market Size of Bronchiolitis

16.3.2.2. Market Size of Bronchiolitis by Therapies

16.3.3. Italy

16.3.3.1. Total Market Size of Bronchiolitis

16.3.3.2. Market Size of Bronchiolitis by Therapies

16.3.4. Spain

16.3.4.1. Total Market Size of Bronchiolitis

16.3.4.2. Market Size of Bronchiolitis by Therapies

16.3.5. United Kingdom

16.3.5.1. Total Market Size of Bronchiolitis

16.3.5.2. Market Size of Bronchiolitis by Therapies

16.4. Japan

16.4.1. Total Market Size of Bronchiolitis

16.4.2. Market Size of Bronchiolitis by Therapies

17. KOL Views

18. Market Drivers

19. Market Barriers

20. SWOT Analysis

21. Unmet Needs

22. Appendix

22.1. Bibliography

22.2. Report Methodology

23. DelveInsight Capabilities

24. Disclaimer

25. About DelveInsight

List of Table

Table 1: Summary of Bronchiolitis, Market and Epidemiology (2018–2030)

Table 2: Incident Patient Population of Bronchiolitis in the 7MM (2018–2030)

Table 3: Incidence of Bronchiolitis in the US (2018–2030)

Table 4: Incidence of Bronchiolitis by Etiologies in the US (2018–2030)

Table 5: Incidence of Bronchiolitis in Germany (2018–2030)

Table 6: Incidence of Bronchiolitis by Etiology in Germany (2018–2030)

Table 7: Incidence of Bronchiolitis in France (2018–2030)

Table 8: Incidence of Bronchiolitis by Etiology in France (2018–2030)

Table 9: Incidence of Bronchiolitis in Italy (2018–2030)

Table 10: Incidence of Bronchiolitis by Etiology in Italy (2018–2030)

Table 11: Incidence of Bronchiolitis in Spain (2018–2030)

Table 12: Incidence of Bronchiolitis by Etiologies in Spain (2018–2030)

Table 13: Incidence of Bronchiolitis in the UK (2018–2030)

Table 14: Incidence of Bronchiolitis by Etiology in the UK (2018–2030)

Table 15: Incidence of Bronchiolitis in Japan (2018–2030)

Table 16: Incidence of Bronchiolitis by Etiology in Japan (2018–2030)

Table 17: Organizations contributing towards Bronchiolitis

Table 18: MV130, Clinical Trial Description, 2021

Table 19: Nirsevimab, Clinical Trial Description, 2021

Table 20: RSV F, Clinical Trial Description, 2021

Table 21: MK-1654, Clinical Trial Description, 2021

Table 22: MK-0476, Clinical Trial Description, 2021

Table 23: Suptavumab, Clinical Trial Description, 2021

Table 24: 7MM Market Size of Bronchiolitis in USD Million (2018–2030)

Table 25: Market Size of Bronchiolitis by Therapies in USD Million (2018–2030)

Table 26: Total Market Size of Bronchiolitis in USD Million (2018–2030)

Table 27: Market Size of Bronchiolitis by Therapies in USD Million (2018–2030)

Table 28: Total Market Size of Bronchiolitis in USD Million (2018–2030)

Table 29: Market Size of Bronchiolitis by Therapies in USD Million (2018–2030)

Table 30: Total Market Size of Bronchiolitis in USD Million (2018–2030)

Table 31: Market Size of Bronchiolitis by Therapies in USD Million (2018–2030)

Table 32: Total Market Size of Bronchiolitis in USD Million (2018–2030)

Table 33: Market Size of Bronchiolitis by Therapies in USD Million (2018–2030)

Table 34: Total Market Size of Bronchiolitis in USD Million (2018–2030)

Table 35: Market Size of Bronchiolitis by Therapies in USD Million (2018–2030)

Table 36: Total Market Size of Bronchiolitis in USD Million (2018–2030)

Table 37: Market Size of Bronchiolitis by Therapies in USD Million (2018–2030)

Table 38: Total Market Size of Bronchiolitis in USD Million (2018–2030)

Table 39: Market Size of Bronchiolitis by Therapies in USD Million (2018–2030)

List of Figures

Figure 1: Classification of Bronchiolitis

Figure 2: Factors that Contribute to the Severity of Viral Bronchiolitis

Figure 3: Binding and Entry of RSV into the Host Cell

Figure 4: Factors Influencing the Pathogenesis and Clinical Disease Caused by RSV Infection

Figure 5: Potential role of Neutophil in RSV Bronchiolitis

Figure 6: A schematic Model for Targeting Excessive Neutrophil Homeostasis and Function

Figure 7: Incidence of Bronchiolitis in the 7MM Countries (2018–2030)

Figure 8: Incidence of Bronchiolitis in the US (2018–2030)

Figure 9: Incidence of Bronchiolitis by Etiologies in the US (2018–2030)

Figure 10: Incidence of Bronchiolitis in Germany (2018–2030)

Figure 11: Incidence of Bronchiolitis by Etiologies in Germany (2018–2030)

Figure 12: Incidence of Bronchiolitis in France (2018–2030)

Figure 13: Incidence of Bronchiolitis by Etiologies in France (2018–2030)

Figure 14: Incidence of Bronchiolitis in Italy (2018–2030)

Figure 15: Incidence of Bronchiolitis by Etiologies in Italy (2018–2030)

Figure 16: Incidence of Bronchiolitis in Spain (2018–2030)

Figure 17: Incidence of Bronchiolitis by Etiologies in Spain (2018–2030)

Figure 18: Incidence of Bronchiolitis in the UK (2018–2030)

Figure 19: Incidence of Bronchiolitis by Etiologies in the UK  (2018–2030)

Figure 20: Incidence of Bronchiolitis in Japan (2018–2030)

Figure 21: Incidence of Bronchiolitis by Etiologies in Japan (2018–2030)

Figure 22: Algorithm for Medical Management of Bronchiolitis

Figure 23: 7MM Market Size of Bronchiolitis in USD Million (2018–2030)

Figure 24: Market Size of Bronchiolitis by Therapies in USD Million (2018–2030)

Figure 25: Total Market Size of Bronchiolitis, USD Million (2018–2030)

Figure 26: Market Size of Bronchiolitis by Therapies in USD Million (2018–2030)

Figure 27: Total Market Size of Bronchiolitis, USD Million (2018–2030)

Figure 28: Market Size of Bronchiolitis by Therapies in USD Million (2018–2030)

Figure 29: Total Market Size of Bronchiolitis, USD Million (2018–2030)

Figure 30: Market Size of Bronchiolitis by Therapies in USD Million (2018–2030)

Figure 31: Total Market Size of Bronchiolitis, USD Million (2018–2030)

Figure 32: Market Size of Bronchiolitis by Therapies in USD Million (2018–2030)

Figure 33: Total Market Size of Bronchiolitis, USD Million (2018–2030)

Figure 34: Market Size of Bronchiolitis by Therapies in USD Million (2018–2030)

Figure 35: Total Market Size of Bronchiolitis, USD Million (2018–2030)

Figure 36: Market Size of Bronchiolitis by Therapies in USD Million (2018–2030)

Figure 37: Total Market Size of Bronchiolitis, USD Million (2018–2030)

Figure 38: Market Size of Bronchiolitis by Therapies in USD Million (2018–2030)

Inmunotek
Sanofi
AstraZeneca
Novavax
Merck
Regeneron

 

Forward to Friend

Need A Quote